Statins, widely prescribed as cholesterol-lowering drugs, have recently been extensively studied for their pleiotropic effects on immune systems, especially their beneficial effects on autoimmune and inflammatory disorders. However, the mechanism of statin-induced immunosuppression is far from understood. Here, we found that atorvastatin promoted the expansion of myeloid-derived suppressor cells (MDSCs) both in vitro and in vivo. Atorvastatin-derived MDSCs suppressed T-cell responses by nitric oxide production. Addition of mevalonate, a downstream metabolite of 3-hydroxy-3-methylglutaryl coenzyme A reductase, almost completely abrogated the effect of atorvastatin on MDSCs, indicating that the mevalonate pathway was involved. Along with the amelioration of dextran sodium sulphate (DSS) -induced murine acute and chronic colitis, we observed a higher MDSC level both in spleen and intestine tissue compared with that from DSS control mice. More importantly, transfer of atorvastatin-derived MDSCs attenuated DSS acute colitis and T-cell transfer of chronic colitis. Hence, our data suggest that the expansion of MDSCs induced by statins may exert a beneficial effect on autoimmune diseases. In summary, our study provides a novel potential mechanism for statins-based treatment in inflammatory bowel disease and perhaps other autoimmune diseases.
Introduction
Statins are inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme that catalyses the conversion of HMG-CoA to mevalonate in cholesterol synthesis. Statins have been used extensively as cholesterol-lowering agents and for the treatment of cardiovascular disease. However, accumulating evidence has demonstrated that statins have extensive immunomodulatory and anti-inflammatory properties in addition to their essential role in lipid lowering. [1] [2] [3] In recent years, considerable interest has arisen in statinbased therapy of autoimmune and inflammatory disorders. 1, 2, 4 Studies have found that statin treatment results in an improved clinical outcome in animal models of murine colitis, [5] [6] [7] [8] [9] experimental autoimmune encephalomyelitis, 10, 11 arthritis 12 and systemic lupus erythematosus. 13 These beneficial effects are partly attributed to statins' immunomodulatory role in suppressing T helper type 1 and type 17 responses, while promoting T helper type 2 responses. 1, 2 Atorvastatin (Lipitor), a current extensively prescribed statin drug, has recently gained much attention in inflammatory bowel disease due to its immunomodulating Abbreviations: CFSE, 5,6 carboxyfluorescein diacetate, succinimidyl ester; CM-H2DCFDA, 5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein diacetate, acetyl ester; DSS, dextran sodium sulphate; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-MDSCs, granulocytic MDSCs; HMG-CoA, 3- property. 1, 2 In an animal model of acute experimental colitis, atorvastatin significantly inhibited systemic tumour necrosis factor-a, interleukin-17 (IL-17) and IL-23 levels. 5 Several studies also obtained promising results in atorvastatin-based treatment of Crohn's disease. [14] [15] [16] Despite the extensive studies on statin-mediated immunomodulation and anti-inflammatory effects, the detailed mechanism is not completely understood.
Myeloid-derived suppressor cells (MDSCs) are defined as a heterogeneous population of pathologically activated immature cells and exert a negative regulation of the immune responses in cancer, autoimmunity, inflammatory conditions, trauma and infections. [17] [18] [19] [20] In mice, MDSCs simultaneously express CD11b and Gr-1, which can be further divided into two different subsets [monocytic MDSCs (M-MDSCs) and granulocytic MDSCs (G-MDSCs)], based on their expression of Ly6C and Ly6G, respectively. 21, 22 These two subsets differ in their tissue localization, antigen presentation and immunosuppressive mechanism. 22 Human MDSCs are generally defined as HLA-DR À/low CD11b + CD33 + cells. 23 A variety of cytokines and growth factors [such as granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor, IL-6, interferon-c (IFN-c), IL-1b and IL-13] in the tumour environment can induce MDSC expansion or activation by activating certain signalling pathways, especially Janus kinase/singal transducer and activator of transcription (JAK/STAT) pathway. 24, 25 MDSCs then display a potent immune suppressive activity towards various immune cells, especially T cells, mainly by the L-arginine metabolic pathway. 17, 18 Recently, a number of studies have shown that MDSCs have beneficial effects on inflammatory bowel disease, [26] [27] [28] asthma, 29 rheumatoid arthritis, 30 multiple sclerosis 31 and pregnancy. 32 Hence, drugs with few side effects that promote MDSC expansion under these conditions may improve clinical outcomes.
Here, we found that atorvastatin, a widely prescribed drug in the statin family, remarkably promotes mouse G-MDSC expansion both in vitro and in vivo. Furthermore, the atorvastatin-induced G-MDSCs can attenuate murine acute and chronic colitis. Hence, our study provides a novel immunomodulation pathway of statins in inflammatory bowel disease and other autoimmune disorders.
Materials and methods
Mice C57BL/6 and BALB/c mice were purchased from the Laboratory Animal Centre of Sun Yat-Sen University. Rag1 À/À mice (B6.129S7-Rag1 tm1Mom /JNju) were purchased from the Model Animal Research Centre of Nanjing University. All mice were housed under specific pathogen-free conditions and used at an age of 6-8 weeks. All mouse experimental procedures were approved by the Institutional Animal Care and Use Committee of Sun Yat-Sen University (approval No. IACUC-DB-16-0507).
Reagents and antibodies
RPMI-1640, fetal bovine serum, 2-mercaptoethanol, penicillin, streptomycin, 5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) and 5,6 carboxyfluorescein diacetate, succinimidyl ester (CFSE) were obtained from Invitrogen (Grand Island, NY). Dextran sodium sulphate (DSS) (MW 36 000-50 000) was obtained from MP Biomedicals (Solon, OH). Recombinant murine GM-CSF, IL-6 and human GM-CSF and IL-6 were purchased from Peprotech (Oak Park, CA). NW-hydroxynor-arginine and L-NG-monomethyl-arginine (L-NMMA) were obtained from Cayman Chemical (Ann Arbor, MI). Atorvastatin calcium salt trihydrate, N-acetyl-L-cysteine, L-arginine, cucurbitacin I hydrate (JSI-124), DMSO, castor oil and mevalonolactone were purchased from Sigma-Aldrich (St Louis, MO). The following anti-mouse antibodies were purchased from eBioscience (San Diego, CA): CD3e-phycoerythrin (PE), CD4-PE-Cy5, CD45RB-PE, CD8a-PE, Gr-1-PE-Cy5, CD11b-PE-Cy7, CD11c-PE-Cy5 and their corresponding isotype antibodies. Anti-human antibodies: CD11b-FITC, CD33-PE and HLA-DR-allophycocyanin were also purchased from eBioscience. Ly6G-PE-Cy7, Ly6C-PE and CD11b-FITC were obtained from BD Biosciences (San Jose, CA). MHC Class II-PE and the mouse myeloid-derived suppressor cell isolation kit were from Miltenyi Biotec (Auburn, CA).
Generation of mouse MDSCs in vitro
To generate MDSCs in vitro, 2 million bone marrow cells from the mouse femurs and tibias were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 20 ng/ml GM-CSF, 50 lM 2-mercaptoethanol, with or without 20 ng/ml IL-6, as described previously. 33, 34 The cultures were kept at 37°in a 5% CO 2 -humidified atmosphere in 24-well plates. Media were half changed on day 3. Cells were analysed by flow cytometry on day 5.
T-cell proliferation assay
T-cell proliferation was performed by CFSE dilution as previously described. 34 Briefly, sorted CD3 + T cells containing CD4 + T cells and CD8 + T cells from BALB/c mice were labelled with CFSE (2 lM) (Invitrogen), stimulated with anti-mouse CD3 (5 lg/ml) coated plates and soluble anti-mouse CD28 (1 lg/ml) antibody (eBioscience) and cultured alone or co-cultured with allogeneic MDSCs (from C57BL/6 mice) at different ratios for 3 days. Cells were then stained with CD4-PE-Cy5 and CD8a-PE antibodies, and T-cell proliferation was analysed by flow cytometry.
Atorvastatin treatment
For atorvastatin administration in vivo, C57BL/6 female mice (6-8 weeks) were injected intraperitoneally with 50 mg/kg/day atorvastatin dissolved in 50 ll 5% DMSO/ castor oil. Controls received the vehicle (5% DMSO/castor oil, 50 ll) via the same route. The same dose of atorvastatin for mice was used as described earlier. 9, 35 Mouse weight was monitored daily and mice were killed at day 12.
Induction of DSS colitis
Murine acute colitis was induced by giving 2Á5% DSS (MW 36 000-50 000; MP Biomedicals, Solon, OH) dissolved in drinking water as previously described. 36 Atorvastatin (50 mg/kg/day) or vehicle was injected intraperitoneally for 3 days. After that, mice were injected daily with atorvastatin (atorvastatin alone and DSS + atorvastatin group) or vehicle (the control and DSS alone group). Control mice (n = 6) received drinking water without DSS. Mice were killed at day 10. For chronic DSS colitis induction, mice were given 2% DSS for 7 days followed by 14 days of drinking water. 37 This cycle was repeated three times. Atorvastatin or vehicle was injected intraperitoneally for 3 days before each DSS administration and lasted for 12 days. Mice were killed at day 55. For the induction of DSSinduced chronic colitis in Rag1 À/À mice, mice were given 2% DSS for 5 days followed by 5 days of drinking water. 38, 39 This cycle was repeated three times. Atorvastatin or vehicle was injected intraperitoneally for 3 days before DSS administration and lasted to the end. All the mice were killed at day 33.
To evaluate the colitis severity, animals were monitored daily for loss of body weight, daily stool consistency, haematochezia as previously described. 6, 37 Disease activity index was determined as the combined scores of (i) weight loss, (ii) stool consistency, and (iii) bleeding divided by 3. Each score was obtained as follows: by change in weight (0, ≤ 1%; 1, 1-5%; 2, 5-10%; 3, 10-15%; 4, ≥ 15%), haemoccult positivity (0, negative; 2, positive; 4, gross bleeding), and stool consistency (0, normal; 2, loose stools; 4, diarrhoea). Colon length as an indirect marker of inflammation was also recorded. After removing the caecum, the rest of the colon was cut into proximal and distal halves. Tissue was fixed in 3% buffered formalin, paraffin-embedded, sectioned, and stained with haematoxylin & eosin for histological examination and scored as described previously. 37 
Flow cytometry and sorting
Single cell suspensions were stained with specific fluorescein-conjugated antibodies and the proportions of different cell populations were obtained by a BD LSRII flow cytometer (BD Biosciences, San Jose, CA). All data were analysed by FLOWJO software (Tree Star, Ashland, OR).
For flow cytometric sorting, cultured bone marrow cells or mouse splenocytes were stained with anti-mouse Gr-1 and CD11b antibodies and CD11b + Gr-1 high G-MDSCs were isolated by cell sorting on a FACS Aria cell sorter (BD, Mountain View, CA). For isolation of T cells, mouse splenocytes were stained with CD3e-PE antibody and CD3 + T cells were isolated by flow cytometric sorting. The purity of all sorted cells was 97-98%.
Adoptive transfer experiments
Adoptive transfer of G-MDSCs was carried out as described previously. 27, 40 Briefly, G-MDSCs (Gr-1 high Ly6G + , 97-98% purity) or control cells with the same phenotype were enriched using an MDSC isolation kit (Miltenyi Biotec) from the spleen of atorvastatin-treated mice or control mice using two LS columns, followed by tail-vein injection (2 million cells) into each mouse on day 2 post-DSS treatment. After that, the same numbers of G-MDSCs were injected intravenously into recipient mice every 4 days. Mice were killed at day 10.
The T-cell transfer model of colitis was performed following the procedures described previously. 41 Briefly, Rag1 À/À mice were injected intraperitoneally with 5 9 10 5 fluorescence-activated cell sorted CD4 + CD45RB high T cells from C57BL/6 mice (purity 97-98%), 5 9 10 5 CD4 + CD45RB high T cells + 5 9 10 5 G-MDSCs (Gr-1 high Ly6G + ) or 5 9 10 5 control cells with the same phenotype from the spleens of mice after atorvastatin or vehicle treatment. After that, the same number of G-MDSCs and control cells were transfered into recipient mice every 4 days and lasted for 2 weeks. Mice were killed at 8 weeks post-injection when they had lost 15-20% of their original body weight.
NO production
The assay was performed following the same procedures described previously. 42 
Reactive oxygen species production
Reactive oxygen species (ROS) level was measured by flow cytometry using CM-H2DCFDA (Invitrogen) following procedures described earlier. 34 
Quantative real-time PCR
Quantitative real-time RT-PCR was performed as described earlier. 43 Briefly, total RNA was extracted with Trizol (Invitrogen) according to the manufacturer's protocols, and cDNA was synthesized using a SuperScript III reverse transcriptase kit (Qiagen, Valencia, CA). Quantitative RT-PCR was performed in triplicate with SYBR Green (TakaRa, Otsu, Japan) with gene-specific primers (see Supplementary material, Table S1 ).
Human peripheral blood mononuclear cells isolation and generation of human MDSCs in vitro
Human peripheral blood mononuclear cells from healthy volunteer donors were isolated by Ficoll centrifugation as described earlier, 41 followed by culturing the cells in the presence of 10 ng/ml GM-CSF and IL-6 to generate human MDSCs as described previously. 44 
Statistics
Statistical analysis was performed by GRAPHPAD PRISM Version 5.0a (GraphPad Software Inc., San Diego, CA, USA) and SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Differences between the two groups were assessed by unpaired Student's t-tests and one-way analysis of variance, followed by Dunnett's post hoc test, was used to compare the differences between more than two groups. P < 0Á05 was considered significant.
Results

Atorvastatin promotes MDSC expansion in vitro
To investigate whether atorvastatin influences MDSC expansion, we first cultured mouse bone marrow cells in the presence of GM-CSF with or without IL-6 as described previously. 33 After 5 days, phenotype was evaluated by flow cytometry. Atorvastatin significantly increased the frequency of MDSCs (CD11b + Gr-1 + ) from 34Á9 to 57Á4% (Fig. 1a) ; the total number of cultured cells was not affected. Further, we analysed the subset of MDSCs and data showed that the CD11b + Ly6G + Ly6C À/low G-MDSC population, not CD11b + Ly6G À Ly6C high M-MDSCs, was significantly elevated by atorvastatin ( Fig. 1a ). Meanwhile, a dramatic reduction of CD11c + MHC-II + dendritic cells (DCs) frequency was observed upon atorvastatin administration ( Fig. 1a ), indicating a deficiency in myeloid differentiation.
Based on the fact that MDSCs can dampen T-cell immune responses under pathological conditions, 17 we next evaluated the suppressive activity of atorvastatininduced MDSCs. Mouse bone marrow cells were cultured in the presence of GM-CSF and IL-6 with or without atorvastatin treatment in vitro for 5 days. As CD11b + Gr-1 high MDSCs correspond to G-MDSCs (see Supplementary material, Fig. S1 ), we sorted CD11b + Gr-1 high MDSCs and co-cultured with CFSE-labelled allogeneic T cells at different ratios; CD4 + and CD8 + T-cell proliferation was determined after 3 days. Atorvastatin-derived MDSCs exerted a strong suppressive activity towards T-cell proliferation, but no difference was observed when compared with control ( Fig. 1b ). Together, these results suggest that atorvastatin could promote the expansion of MDSCs in vitro.
Atorvastatin promotes MDSCs accumulation in vivo
Next, we investigated whether atorvastatin can induce MDSC accumulation in vivo. C57BL/6 mice were administered intraperitoneally with atorvastatin or vehicle control. After 12 days, the frequency of MDSCs in spleen, bone marrow, liver and peripheral blood was determined by flow cytometry. We found consistently higher levels of CD11b + Ly6G + Ly6C À/low cells in these tissues from mice treated with atorvastatin than in those from control mice, whereas no differences in the frequency of CD11b + Ly6G À Ly6C high cells were observed ( Fig. 2a ). Previous studies have demonstrated that CD11b + Gr-1 + cells from naive mice are not immunosuppressive and are regarded as immature myeloid cells. 45, 46 To determine whether the accumulated population of CD11b + Ly6G + Ly6C À/low cells were G-MDSCs, we performed a T-cell proliferation assay and found that this subset from atorvastatin-treated mouse spleen were immunosuppressive, whereas the cells from control mice were non-suppressive ( Fig. 2b) . Moreover, we also found that CD11b + Gr-1 high cells from liver, peripheral blood mononuclear cells, but not bone marrow were immunosuppressive in atorvastatin groups, but were nonsuppressive in control groups (see Supplementary material, Fig. S2 ). These observations indicated that atorvastatin induces G-MDSC accumulation in vivo.
Atorvastatin-derived MDSCs inhibited T-cell responses by nitric oxide production
It is well known that L-arginine and its metabolic products are important for the suppressive function of MDSCs under certain conditions. 17, 18 To investigate the functional mechanism of atorvastatin-derived MDSCs, we firstly analysed mRNA expression of the genes related to MDSCs by quantitative RT-PCR. 34 Intriguingly, we observed that the expression of inducible nitric oxide synthase (iNOS) was significantly increased, whereas no effect was observed for other genes, including all the components of the nicotinamide adenine dinucleotide phosphate-oxidase complex (NADPH) (Fig. 3a) . We next added different inhibitors of L-arginine metabolism into MDSCs and T-cell co-culture systems. As expect, addition of the iNOS inhibitor L-NMMA almost completely abrogated the suppressive effect of atorvastatin-derived G-MDSCs (Fig. 3b ), accompanied by a clear lower level of NO content by L-NMMA treatment (Fig. 3c ). No effect of L-NMMA on cultured T cells alone was observed, indicating that the suppression was mediated through MDSCs (data not shown). Moreover, there was no difference in ROS level between MDSCs and immature myeloid cells from the spleen and bone marrow of mice treated with atorvastatin and vehicle, respectively (Fig. 3d ). These results support that atorvastatin-derived MDSCs suppress T-cell in an NO-dependent manner. Statins block cholesterol synthesis by inhibiting the HMG-CoA reductase, which catalyses the conversion of HMG-CoA to mevalonic acid. 1 To determine whether the effect of atorvastatin on MDSC expansion was dependent on the mevalonate pathway, we asked whether mevalonate could reverse atorvastatin's effect. We found that the addition of mevalonate at the initial culture of bone marrow cells in the presence of atorvastatin prevented MDSC expansion (Fig. 3e) . These results confirmed that the expansion of MDSCs caused by atorvastatin was a consequence of the inhibition of HMG-CoA reductase.
Atorvastatin-derived MDSCs attenuate DSS-induced acute colitis
Previous studies have demonstrated that statins have therapeutic benefits for the treatment in animal models of autoimmune disease, including inflammatory bowel disease. 1, 5, 9 Intriguingly, a number of studies have shown beneficial effects of MDSCs in treating inflammatory bowel disease (IBD). [26] [27] [28] [47] [48] [49] We therefore speculated that atorvastatin-derived G-MDSCs may reduce the severity of murine experimental colitis. To this end, we firstly performed atorvastatin administration during DSS-induced acute colitis ( Fig. 4a) . Consistent with previous studies, 9 our results showed that administration of atorvastatin significantly reduced the severity of murine colitis as assessed by body weight loss (Fig. 4b ), colon length ( Fig. 4c ) and disease activity index (Fig. 4d ) compared with the DSS control group. Histological analysis also showed an improvement in colonic histology upon atorvastatin co-treatment ( Fig. 4e,f ). In addition, we observed the accumulation of MDSCs in mouse spleen, mesenteric lymph nodes (mLN), Peyer's patches (PP) and colonic lamina propria mononuclear cells (LPMCs) after DSS administration (Fig. 4g ). More importantly, the frequency of MDSCs (CD11b + Gr-1 + ) from DSS-atorvastatin co-treated mice was higher in spleen, mLN, PP and LPMCs than that from DSS control mice (Fig. 4g ). Further, we found that the elevation of MDSCs was mainly derived from the G-MDSC subset ( Fig. 4h , and see Supplementary material, Fig. S3 ). These observations suggest that the G-MDSCs induced by atorvastatin may contribute to the improvement of murine colitis induced by atorvastatin. For further confirmation, we transferred atorvastatinderived G-MDSCs in vivo or immature myeloid cells into naive C57BL/6 mice to see whether these cells can attenuate DSS-induced colitis (Fig. 5a ). As expected, the frequency of G-MDSCs in mouse spleen and peripheral blood mononuclear cells, but not M-MDSCs, dramatically increased after transferring G-MDSCs (Fig. 5b) . Results indicated that adoptive transfer of atorvastatinderived G-MDSCs, but not the corresponding control cells from naive mice, attenuated murine experimental colitis as characterized by less body weight loss (Fig. 5c ), lower disease activity index (Fig. 5d ), longer colon length ( Fig. 5e ) and less colon inflammation ( Fig. 5f ,g) compared with DSS control mice. In addition, the level of G-MDSCs in mouse spleen and LPMCs was much higher in the DSS+Ator-MDSCs group than in the control group (Fig. 5h) . These observations support that atorvastatin-derived G-MDSCs attenuate DSS-induced acute colitis.
Atorvastatin-derived MDSCs attenuate chronic colitis
The main feature of atorvastatin-derived G-MDSCs is their immunosuppressive function towards T cells. 17 Although some evidence shows that T lymphocytes may be a driving factor in DSS-induced acute colitis, 50,51 chronic DSS colitis is typically augmented by T lymphocytes. 37,52 Therefore, we next investigated a chronic DSS colitis model (Fig. 6a) . Consistent with the acute colitis results, atorvastatin administration attenuated chronic DSS colitis characterized by the amelioration in body weight loss (Fig. 6b ), disease activity index (Fig. 6c ), colon length ( Fig. 6d ) and colon inflammation (Fig. 6e) . Notably, we also found that G-MDSC level in mouse spleen, mLN, PP and colon LPMCs from the DSS+atorvastatin group was much higher than that from the DSS group. Analysis of MDSC subsets showed a significant enhancement of G-MDSCs. Hence, our studies suggest that atorvastatin-induced MDSCs may mediate the beneficial effects of atorvastatin in chronic colitis by inhibiting T-cell responses. To support our speculation, we next carried out the DSS-induced chronic colitis in Rag1 À/À mice, which have no T cells and B cells. As expected, no beneficial effects of atorvastatin were observed for DSS and atorvastatin co-treatment in Rag1 À/À mice when compared with the DSS group, although atorvastatin induced G-MDSC production (see Supplementary material, Fig. S4 ). Hence, atovastatin-induced MDSCs probably attenuate DSS-induced chronic colitis by suppressing T-cell responses.
To directly confirm the beneficial effects of atorvastatin-induced G-MDSCs in chronic colitis, we asked whether atorvastatin-induced G-MDSCs can attenuate chronic colitis in a T-cell transfer model of colitis in Rag1 À/À mice. 41 As expected, we observed that co-transfer of CD4 + CD45RB high cells and atorvastatin-induced G-MDSCs, but not the immature myeloid cells, ameliorated the colitis as assessed by weight loss (Fig. 7a ), colon length ( Fig. 7b ) and histological score (Fig. 7c ). Meanwhile, the absolute numbers of CD4 + T cells in spleen, mLN and colon LPMCs of mice in the CD45RB high +MDSCs group were much lower than that of control groups (Fig. 7d ). Therefore, we concluded that atorvastatin-induced MDSCs attenuated chronic colitis mainly by inhibiting T-cell responses. 
Discussion
Compelling evidence generated from extensive clinical and laboratory studies now exists that statins have therapeutic benefits for the treatment of inflammatory and autoimmune disorders. 1, 2 The mechanisms of statins therapy, however, are not fully understood. In this study, we show that atorvastatin promotes MDSC expansion and attenuates experimental murine colitis. Our finding therefore provides a novel mechanism for the immunomodulation of statins in the treatment of inflammatory bowel disease and perhaps other autoimmune disorders.
The MDSCs are derived from a differentiation deficiency of common myeloid progenitor cells and granulocyte and macrophage progenitor cells under pathological conditions, including autoimmune disease. 25 In recent years, attention has been paid to statins therapy in autoimmune diseases because of their extensive immunomodulatory effects. 1,2 However, to our knowledge, little is known about the effect of statins on MDSC production and function. Our studies suggest that atorvastatin could remarkably promote G-MDSC expansion both in vitro and in vivo. Meanwhile, along with the increase of MDSC frequency, a clear reduction in the proportion of immature dendritic cells was observed in the culture system in vitro (Fig. 1a ). Previous studies also show that atorvastatin inhibits dendritic cell development and function. 53, 54 Accordingly, atorvastatin may impair myeloid cell development, so enhancing the accumulation of MDSCs. We further found that the effect of atorvastatin on MDSC expansion was dependent on its inhibition on the mevalonate pathway. Addition of mevalonate almost completely abrogated atorvastatin-induced MDSC expansion. However, the mechanism of atorvastatin-induced MDSC expansion still remains to be understood. Zoledronate, a nitrogen-containing bisphosphonate blocking farnesylpyrophosphate synthesis in the mevalonate pathway, was shown to enhance the increase of immature myeloid cells with MDSC characteristics in a model of murine mesothelioma. 55 The effect of atorvastatin on G-MDSC expansion may be associated with statins' ability to inhibit protein prenylation mediated by farnesylpyrophosphate and geranylgeranylpyrophosphate, two important intermediate metabolites in the mevalonate pathway. 1 The underlying mechanism requires further investigation.
Additionally, atorvastatin-derived MDSCs suppressed T-cell proliferation by NO production as addition of the iNOS inhibitor L-NMMA totally recovered T-cell responses. As expected, we found that atorvastatinderived MDSCs expressed higher iNOS mRNA than control cells. Moreover, our preliminary study showed that atorvastatin-derived MDSCs also expressed higher levels IL-1b and IFN-c than controls, whereas the mRNA level of S100A8, S100A9, Cox-2, IL-10 and transforming growth factor-b did not change (see Supplementary material, Fig. S5 ). Since the expression of iNOS could be induced by IFN-c and IL-1b via JAK/STAT1 signalling, 18 we speculate that atorvastatin may enhance the iNOS expression through this pathway but this requires further investigation. The up-regulation of IL-1b and IFN-c induced by statins has been reported previously. 56, 57 Although simvastatin has been found to inhibit IFN-cinduced CD40 gene expression by suppressing STAT1a in macrophages and microglia, 58 mevastatin increases STAT1 activation and restores nitric oxide synthase (NOS2 or iNOS) expression in models of cystic fibrosis epithelium. 59 However, how atorvastatin induces iNOS expression in MDSCs warrants further studies.
Consistent with previous studies, 5, 9 we found that atorvastatin attenuated murine experimental colitis. To interpret the beneficial effects, early reports mainly focused on the negative regulation of statins on pro-inflammatory factors (such as tumour necrosis factor-a and IL-17), or the up-regulation of eNOS expression. 5, 7 The mechanism, however, is not fully understood. D€ abritz et al. found that the resistance to murine colitis in gp130 757F/F mice is dependent on STAT3-mediated G-MDSC expansion, suggesting a beneficial role of G-MDScs in inflammatory bowel disease. 49 We found that the attenuation of both DSS-induced acute and chronic colitis after atorvastatin treatment was coupled with a much higher level of G-MDSCs than DSS control mice. Meanwhile, no beneficial effects were observed in DSS-induced chronic colitis in Rag1 À/À mice that have no T and B cells. More importantly, we discovered that transfer of atorvastatin-derived G-MDSCs attenuated the severity of DSS-induced acute colitis and T-cell transfer of chronic colitis. Although T-cell responses may also participate in DSS acute colits, 50, 51 ,a chronic colitis model mainly involves adaptive immune responses. 37 Therefore our results showed that atorvastatin-induced MDSCs attenuate murine colitis mainly by inhibiting T-cell responses. Additionally, we also found that atorvastatin could promote human MDSCs (HLA-DR À/low CD11b + CD33 + cells) expansion in vitro (see Supplementary material, Fig. S6 ), implying that atorvastatin-derived MDSCs may also ameliorate Crohn's disease and other autoimmune disorders in human.
In conclusion, our study provides information that atorvastatin promotes MDSC expansion, thus shedding new light on the immunomodulation of statins. The effect of atorvastatin on MDSC accumulation may represent another pathway for statins' therapeutic benefits in treating IBD and other autoimmune diseases.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Figure S1 . Gating strategy for sorting mouse granulocytic myeloid-derived suppressor cells (G-MDSCs). CD11b + Gr-1 high and CD11b + Gr-1 low cells were gated, respectively. Then, the expression of Ly6G and Ly6C was analysed. CD11b + Gr-1 high cells represents G-MDSCs; CD11b + Gr-1 low represents monocytic (M-) MDSCs. Figure S2 . The suppressive function of granulocytic myeloid-derived suppressor cells (G-MDSCs; CD11b + Gr-1 high ) from bone marrow (BM), liver and peripheral blood mononuclear cells (PBMCs) of mice treated with atorvastatin or vehicle. G-MDSCs (CD11b + Gr-1 high ) were purified by flow cytometric sorting. Allogeneic CD3 + T cells containing CD4 + and CD8 + T cells (from BALB/c mice) were stimulated with anti-CD3/CD28 antibodies, and co-cultured with isolated G-MDSCs at the ratio of 2 : 1 for 3 days. CD4 + and CD8 + T-cell proliferation was determined by CFSE dilution. Unstimulated T cells were used as a negative control. Representative data from a single experiment (left), as well as mean+SEM of three independent experiments (right) are shown. Ator, atorvastatin. **P < 0Á01. Figure S3 . Another two representative flow cytometry plots of myeloid-derived suppressor cell (MDSC) subsets (CD11b + cells pre-gated) in the mouse spleen and colon lamina propria mononuclear cells (LPMCs) were evaluated by flow cytometry in Fig. 4(h) . Figure S4 . Atorvastatin did not attenuate dextran sodium sulphate (DSS) -induced chronic colitis in Rag1 À/À mice. (a) The experimental design. Rag1 À/À mice were injected daily intraperitoneally with atorvastatin (50 mg/ kg/day) or vehicle control. Mice were killed at day 33. Chronic colitis was evaluated by: weight loss (b), disease activity index (DAI) (c), colon length (d) and colon histology (100 9) and histology score (e). (f) Proportions of myeloid-derived suppressor cells (MDSCs; CD11b + Gr-1 + ) in spleen and colon lamina propria mononuclear cells (LPMCs) were evaluated by flow cytometry. Representative graph (left) and statistical graph (right) are shown (n = 4). (g) The representative flow cytometry plots of MDSC subsets (with CD11b + cells pregated) in spleen and colon LPMCs for DSS and DSS+Atorvastatin treatment. *P < 0Á05, **P < 0Á01. Figure S5 . The effect of atorvastatin on interferon-c (IFN-c) and interleukin-1b (IL-1b) mRNA expression. (a) mRNA expression of S100A8, S100A9, IL-1b, IFN-c, Cox-2, IL-10 and transforming growth factor-b (TGF-b) was evaluated by quantitative RT-PCR using samples as described in Fig. 3(a) . (b) Mouse bone marrow cells were treated with atorvastatin (5 lM) or DMSO for 24 hr. Then, the cells were collected and the mRNA expression of S100A8 and S100A9, IL-1b, IFN-c, Cox-2, IL-10 and TGFb was measured by quantitative RT-PCR. Figure S6 . Atorvastatin promoted human myeloidderived suppressor cell (MDSC) expansion in vitro. Human peripheral blood mononuclear cells (PBMCs) from healthy volunteers were cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-6 (IL-6) (10 ng/mL) and treated with atorvastatin (5 lM) or mevalonolactone (100 lM) for 6 days. The proportions of human MDSCs (HLA-DR À/ low CD11b + CD33 + ) were evaluated by flow cytometry. (a) Gating strategy of monocytic (M-) MDSCs by flow cytometry analysis. HLA-DR À/low cells were first selected from live PBMCs, and the CD11b + CD33 + population was further gated as human MDSCs. (b) Representative data from a single experiment (left), as well as mean+SEM of three independent experiments (right) are shown. Ctrl, control; Meva, mevalonolactone; Ator, atorvastatin. *P < 0Á05; **P < 0Á01. Table S1 . Sequences of primers used in this study. 
